FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	OVAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,				· ·										
Name and Address of Reporting Person* Kanter Stacy J.							2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics Inc. [APLT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Kanter Stacy J.															X	Director		10%	Owner		
(Last) (First) (Middle) C/O APPLIED THERAPEUTICS, INC.							3. Date of Earliest Transaction (Month/Day/Year) 01/28/2020									Office below	er (give title w)		Other (specify below)		
545 5TH AVENUE, SUITE 1400						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street) NEW YORK NY 10017					-	and the second s									Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(5	State) ((Zip)																		
		Tab	le I - Nor	n-Deriv	ative	Se	curitie	s Acc	uired,	Dis	posed o	f, or	Bene	eficia	ally (Owne	ed				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution if any		Deemed ecution Date, ny onth/Day/Year)		Transaction Disposed Code (Instr. 5)		ties Acquired (A) d Of (D) (Instr. 3,			nd	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount		(A) or (D)	Price	. 1	Transaction(s) (Instr. 3 and 4)			(1130.4)						
Common Stock 01/28/						8/2020					6,500)	A \$45.5		6,500		D				
		Ta	able II - D								sed of, onvertib				y Ov	vned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			8. Price Derivat Securit (Instr. !		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nun of	ount nber res							

Explanation of Responses:

Remarks:

/s/ Shoshana Shendelman, Attorney-in-Fact 01/29/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.